Home » Topics » BioWorld Science

BioWorld Science
RSS

Bayer initiates phase II study of BAY-2586116 in obstructive sleep apnea

March 5, 2020

miR-10a-5p found to be a therapeutic target for treating NSCLC

March 5, 2020

SMARCA4 expression is lost in sinonasal teratocarcinosarcoma

March 5, 2020

Target Biopharmaceutical Technology Shenzhen discloses SN-38 derivatives

March 5, 2020

Lead Discovery Center synthesizes HER2 and EGFR inhibitors

March 5, 2020

Caloric restriction prevents negative aging effects in rats

March 5, 2020

Merck & Co. divulges new IDO1 inhibitors

March 5, 2020

Gudui Biopharma Technology identifies new compounds for stroke

March 5, 2020

Forma Therapeutics patents HDAC6 inhibitors

March 5, 2020

FGL1 as a novel therapeutic target in obesity

March 5, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...